Double Bond Pharmaceutical Investor Relations Material
Latest events
Q1 2025
23 May, 2025
Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Double Bond Pharmaceutical
Access all reports
Double Bond Pharmaceutical International AB is a Sweden-based pharmaceutical company specializing in the development of innovative therapies for cancer and infectious diseases. The company focuses on utilizing advanced drug delivery technologies to improve the efficacy and safety of treatments. Double Bond Pharmaceutical’s research and development efforts aim to address unmet medical needs and provide targeted solutions for patients. The company is headquartered in Uppsala, Sweden, and its shares are listed on the Spotlight Stock Market.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
DBP
Country
🇸🇪 Sweden